Gland Pharma · NSE: GLAND · BSE: 543245
Q1 FY27 results · Apr–Jun 2026
Gland Pharma reported revenue from operations of ₹1,800.27 crore (up 19.6% from Q1 FY26) and net profit of ₹316.96 crore (up 47.1% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,800.27 | 1,505.62 | +19.6% | 1,742.79 | +3.3% |
| Other income | 61.23 | 57.53 | +6.4% | 111.47 | −45.1% |
| Total income | 1,861.50 | 1,563.15 | +19.1% | 1,854.26 | +0.4% |
| Profit before tax | 434.98 | 312.74 | +39.1% | 505.80 | −14.0% |
| Net profit for the period | 316.96 | 215.48 | +47.1% | 366.68 | −13.6% |
| EPS, basic (₹) | 19.23 | 13.08 | +47.0% | 22.26 | −13.6% |
| Net margin (%) | 17.6 | 14.3 | 21.0 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,286.64 | 1,038.84 | +23.9% | 1,261.59 | +2.0% |
| Other income | 58.82 | 54.74 | +7.5% | 106.36 | −44.7% |
| Total income | 1,345.46 | 1,093.58 | +23.0% | 1,367.95 | −1.6% |
| Profit before tax | 487.69 | 362.38 | +34.6% | 564.80 | −13.7% |
| Net profit for the period | 364.39 | 269.26 | +35.3% | 420.45 | −13.3% |
| EPS, basic (₹) | 22.11 | 16.34 | +35.3% | 25.52 | −13.4% |
| Net margin (%) | 28.3 | 25.9 | 33.3 |
Consolidated
- Filed with BSE
- 10 Aug 2026, 17:14 IST
- Board meeting
- 10 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2026, 17:14 IST
- Board meeting
- 10 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE